Oxytocin
Aliases: Oxytocin · Pitocin · Syntocinon
Last verified: 2026-09-23
The short version
A nonapeptide pituitary hormone — approved for labor induction and postpartum bleeding. Nasally investigated/used for social anxiety, autism, bonding and sexual function.
Identity & type
- Molecular type
- peptide
- Origin
- A nonapeptide pituitary hormone — approved for labor induction and postpartum bleeding.
Mechanism of action
Oxytocin receptor agonist (Gq) in uterus, brain (amygdala, hippocampus) and mammary glands.
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. Medical: infusion per protocol. Nasal: 24–40 IU per dose.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Medical: infusion per protocol. Nasal: 24–40 IU per dose. Nasally (off-label): reduced social anxiety, stronger feelings of bonding and intimacy are reported; effects are short (1–2 h) and context-dependent.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Nasally (off-label): reduced social anxiety, stronger feelings of bonding and intimacy are reported; effects are short (1–2 h) and context-dependent.
Protocol — official vs community
Official / label
Approved (Pitocin) for labor: IV dosing by protocol. Intranasal (Syntocinon, where available): 1–2 sprays per nostril for lactation/social indications per label.
- 01Label-defined
Duration: Indication-defined.
The social-sniffing research literature uses single intranasal doses under supervision.
Community (anecdotal)
10–40 IU intranasal single doses, occasionally repeated.
- Cycle:
- Sporadic, event-driven use.
- Break:
- N/A — but tolerance to social effects is plausible with frequent use.
Single-dose social use carries low acute risk; chronic unsupervised use has no data.
Human evidence
Mixed results in autism/social anxiety; reliably increases orgasm/bonding in smaller studies.
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- Nasal: mild; IV: contractions, water retention, hyponatremia at high doses.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Real-world data outside controlled trials